Palatin Technologies (NYSEAMERICAN:PTN) Stock Rating Reaffirmed by HC Wainwright

Palatin Technologies (NYSEAMERICAN:PTN)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $17.00 price target on the biopharmaceutical company’s stock.

Palatin Technologies Stock Performance

PTN stock opened at $0.83 on Tuesday. Palatin Technologies has a 12-month low of $0.68 and a 12-month high of $5.65. The stock has a market capitalization of $16.01 million, a P/E ratio of -0.33 and a beta of 1.01.

Palatin Technologies (NYSEAMERICAN:PTN) last issued its quarterly earnings results on Monday, September 30th. The biopharmaceutical company reported ($0.49) EPS for the quarter. The company had revenue of $0.35 million during the quarter.

Hedge Funds Weigh In On Palatin Technologies

A hedge fund recently bought a new stake in Palatin Technologies stock. XTX Topco Ltd bought a new position in Palatin Technologies, Inc. (NYSEAMERICAN:PTN) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 14,631 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. XTX Topco Ltd owned approximately 0.08% of Palatin Technologies at the end of the most recent reporting period. Institutional investors own 11.50% of the company’s stock.

Palatin Technologies Company Profile

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.